ARCT-165

ARCT-165 is an experimental mRNA vaccine developed for the prevention of diseases caused by the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. This vaccine represents a part of the ongoing efforts to expand the arsenal against COVID-19, utilizing mRNA technology, similar to the approach taken by the Pfizer–BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.

Development and Mechanism

ARCT-165 is developed by Arcturus Therapeutics, a biotechnology company specializing in the development of mRNA medicines for various diseases. The vaccine works by using messenger RNA (mRNA) to instruct cells in the body to produce a protein that is part of the SARS-CoV-2 virus, specifically the spike protein. This protein does not cause disease but triggers the immune system to respond and build immunity to the virus.

The development of ARCT-165 is based on the company's proprietary lipid nanoparticle delivery system, which is designed to enhance the stability and effectiveness of the mRNA. This technology is crucial for ensuring that the mRNA reaches the target cells without being degraded and can produce the viral protein in sufficient quantities to elicit a strong immune response.

Clinical Trials

As of the last update, ARCT-165 is undergoing various stages of clinical trials to evaluate its safety, tolerability, and immunogenicity. These trials are essential for determining the vaccine's efficacy in preventing COVID-19 infection and its potential side effects. The results of these trials will dictate the vaccine's path towards regulatory approval and its role in the global vaccination efforts against COVID-19.

Potential Impact

The development of vaccines like ARCT-165 is critical in the fight against the COVID-19 pandemic. mRNA vaccines have shown great promise due to their ability to be developed and manufactured rapidly compared to traditional vaccine technologies. Additionally, mRNA vaccines can be easily adapted to combat new variants of the virus, offering a flexible tool in the ongoing battle against COVID-19.

If proven effective and safe, ARCT-165 could join the ranks of approved COVID-19 vaccines, contributing to the global vaccination efforts and potentially altering the course of the pandemic. Its success could also validate the use of mRNA technology for future vaccine development against other infectious diseases.

See Also

• COVID-19 vaccine
• mRNA vaccine
• SARS-CoV-2
• Pandemic

Resources

Latest articles - ARCT-165

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on ARCT-165 for any updates.

‎